The European Commission has granted orphan drug designation to CytRx Corporation's arimoclomol for the treatment of amyotrophic lateral sclerosis

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1563, 2006-01, pp. : 23-23

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pfizer's SU 11248 has been granted orphan drug status by the European Commission

By  

Inpharma, Vol. 1, Iss. 1475, 2005-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite

US orphan drug designation granted for MGCD0103

By  

Inpharma, Vol. 1, Iss. 1626, 2008-01 ,pp. : 23-23

Adis International

Access to resources Recommend Favorite

The EMEA has granted Orphan Drug Designation for imisopasem manganese [M40403; ActivBiotics] for the prevention of oral mucositis

By  

Inpharma, Vol. 1, Iss. 1625, 2008-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite

Current Nervous System Related Drug Targets for the Treatment of Amyotrophic Lateral Sclerosis

By  

Current Pharmaceutical Design, Vol. 16, Iss. 18, 2010-06 ,pp. : 2053-2073

Bentham Science Publishers

Access to resources Recommend Favorite

Orphan drug designation in the EU

By  

Inpharma, Vol. 1, Iss. 1578, 2007-01 ,pp. : 23-23

Adis International

Access to resources Recommend Favorite